Amgen (AMGN) Enterprise Value (2009 - 2026)
Amgen (AMGN) recorded quarterly Enterprise Value of -$12.0 billion in Q1 2026, down 31.87% quarter-over-quarter from -$9.1 billion in Q4 2025, and down 36.64% on a YoY basis from -$19.0 billion in Q1 2025.
Amgen (AMGN) Enterprise Value (2009 - 2026) Analysis & Trends
Amgen's Enterprise Value history runs 18 years deep, the most recent figure standing at -$12.0 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 36.64% year-over-year to -$12.0 billion; the TTM figure through Mar 2026 stood at -$12.0 billion (down 36.64% YoY), while the FY2025 annual figure was -$9.1 billion, up 23.75% from the prior year.
- Enterprise Value was -$12.0 billion for Q1 2026 at Amgen, down from -$9.1 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$6.5 billion in Q1 2022 to a low of -$34.7 billion in Q3 2023.
- Historically, Enterprise Value has averaged -$13.7 billion across 5 years, with a median of -$9.4 billion in 2025.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value slumped 382.29% in 2023, then surged 74.06% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$9.3 billion in 2022, then slipped by 17.61% to -$10.9 billion in 2023, then slipped by 9.4% to -$12.0 billion in 2024, then increased by 23.75% to -$9.1 billion in 2025, then tumbled by 31.87% to -$12.0 billion in 2026.
- The last three Enterprise Value figures came in at -$12.0 billion (Q1 2026), -$9.1 billion (Q4 2025), and -$9.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.04 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -9.45 Bn |
| Jun 30, 2025 | -8.03 Bn |
| Mar 31, 2025 | -8.81 Bn |
| Dec 31, 2024 | -11.97 Bn |
| Sep 30, 2024 | -9.01 Bn |
| Jun 30, 2024 | -9.30 Bn |
| Mar 31, 2024 | -9.71 Bn |
| Dec 31, 2023 | -10.94 Bn |
| Sep 30, 2023 | -34.74 Bn |
| Jun 30, 2023 | -34.25 Bn |
| Mar 31, 2023 | -31.56 Bn |
| Dec 31, 2022 | -9.31 Bn |
| Sep 30, 2022 | -11.48 Bn |
| Jun 30, 2022 | -7.18 Bn |
| Mar 31, 2022 | -6.54 Bn |
| Dec 31, 2021 | -8.04 Bn |
| Sep 30, 2021 | -12.92 Bn |
| Jun 30, 2021 | -8.08 Bn |